Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Published:2018-09-27 Issue:3 Volume:104 Page:576-586
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Giménez Neus,Martínez-Trillos Alejandra,Montraveta Arnau,Lopez-Guerra Mónica,Rosich Laia,Nadeu Ferran,Valero Juan G.,Aymerich Marta,Magnano Laura,Rozman Maria,Matutes Estella,Delgado Julio,Baumann Tycho,Gine Eva,González Marcos,Alcoceba Miguel,Terol M. José,Navarro Blanca,Colado Enrique,Payer Angel R.,Puente Xose S.,López-Otín Carlos,Lopez-Guillermo Armando,Campo Elias,Colomer Dolors,Villamor Neus

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virus-driven dysregulation of the BCR pathway: a potential mechanism for the high prevalence of HIV related B-cell lymphoma;Annals of Hematology;2024-08-28

2. Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors—A Literature Review;Journal of Clinical Medicine;2024-08-01

3. A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass;The Oncologist;2024-06-17

4. Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs;Leukemia;2024-06-14

5. Evaluating the Role of Neddylation Modifications in Kidney Renal Clear Cell Carcinoma: An Integrated Approach Using Bioinformatics, MLN4924 Dosing Experiments, and RNA Sequencing;Pharmaceuticals;2024-05-15